Tirzepatide in Arthritis, Psoriatic: NCT07443956 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 28 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Not Applicable
Clinical phase
Recruiting
Recruitment status
45
Planned enrollment
2028-02-01
Primary-completion proxy
Executive view
NCT07443956 evaluates Tirzepatide in Arthritis, Psoriatic. The disclosed sponsor is NHS Greater Glasgow and Clyde, the design is Interventional, and the geographic footprint is United Kingdom. The first listed primary endpoint is Correlation of molecular changes in biopsies (skin, synovial and adipose) with weight loss, assessed over 12 weeks.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07443956 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Arthritis, Psoriatic landscape. Drug & Asset MCP drug_fetch was queried for Tirzepatide, while Company & Deal Intelligence MCP organization_fetch was queried for NHS Greater Glasgow and Clyde.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07443956 | Tirzepatide | Not Applicable / Recruiting | NHS Greater Glasgow and Clyde | United Kingdom | Correlation of molecular changes in biopsies (skin, synovial and adipose) with weight loss 12 weeks | 2028-02-01 |
| CTRI/2026/03/0106289 | Roflumilast | Phase 3 / Not Yet Recruiting | Sponsor not reported | India | Timing not reported | |
| PACTR202603828332085 | Betamethasone | Not Applicable / Complete | Sponsor not reported | Egypt | Timing not reported | |
| NCT07432386 | Apremilast | Phase 4 / Not yet recruiting | Sponsor not reported | Pakistan | Change in Dermatology Life Quality Index (DLQI) Score 8 weeks | 2026-10-14 |
| NCT07432815 | Escitalopram Oxalate | Phase 4 / Recruiting | Cairo University | Egypt | comparison of Percentage change in PASI score from baseline to 6 months between group A and B 6 months | 2026-12-01 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07443956 is a Not Applicable, recruiting study with 45 planned participants. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.
The primary endpoint is “Correlation of molecular changes in biopsies (skin, synovial and adipose) with weight loss” over “12 weeks.” The retrieved endpoint description is: Percentage change in weight (in kg) from baseline will be correlated with changes in molecular markers in tissues (synovium, skin and adipose). This is an experimental medicine (and not efficacy) study that will utilise a range of advanced spatial and other tissue omics to measure molecular markers in these tissues at baseline and 12 weeks. It is not possible or appropriate to specify a single biomarker or measure for this..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 45 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Arthritis, Psoriatic. These records do not establish direct evidence for NCT07443956 unless the registration number matches.
Real-world outcomes of deucravacitinib in Chinese plaque psoriasis patients: a 24-week prospective study
Phase 4; n=101; PASI75(24-week) = 77.2 % Source: https://pubmed.ncbi.nlm.nih.gov/41769731/
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects With Chronic Plaque Psoriasis
Phase 3; n=337; Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) = 26.1 percentage of participants ; Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) = 33.3 percentage of participants Source: https://clinicaltrials.gov/ct2/show/results/NCT04286607
Secukinumab biosimilar BAT2306 versus reference secukinumab in patients with moderate-to-severe plaque psoriasis: a multicentre, double-blind, randomised, active-controlled, phase…
Phase 3; n=502; Adverse Event: nasopharyngitis = The most common treatment-emergent adverse events were upper respiratory tract infections and nasopharyngitis. Source: https://pubmed.ncbi.nlm.nih.gov/42372782/
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Tirzepatide is indexed as Synthetic peptide with GIPR x GLP-1R biology and a global stage of Approved. The asset profile lists Lexaria Bioscience Corp. as an originator or developer.
NHS Greater Glasgow and Clyde is indexed in an unreported country with the website https://www.nhsggc.scot. NHS Greater Glasgow and Clyde delivers hospital, primary care and public health services across the Greater Glasgow and Clyde region. The record lists an unreported number of development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Tirzepatide is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07443956
Protocol source: https://clinicaltrials.gov/study/NCT07443956
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 28 September 2026.
Tirzepatide in Arthritis, Psoriatic is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Correlation of molecular changes in biopsies (skin, synovial and adipose) with weight loss and 2028-02-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
